Reshma Kewalramani on Taking Risks and the Relentless Pursuit of Innovation

Portrait of Reshma Kewalramani
Listen

Reshma Kewalramani already was a nephrologist and researcher in academia when she received the unexpected phone call that changed the course of her career. A biotech executive—the son of her department chair—sought her out for a role at Amgen, the biotechnology company.

That call set her on a course that, decades later, would lead to a career steeped in innovation and advancement, and on the cutting edge of medical research. It also would lead her to Babson College, where she will address the Class of 2023 graduate Commencement ceremony on May 13 and receive an Honorary Doctor of Humane Letters degree.

But, in 2004, the future that Amgen might offer her remained wholly unknown. Kewalramani had always intended to become a doctor. After graduating from medical school, she set out to become what was called a triple threat: She would see patients, teach, and run her own lab. But, her academic lab prioritized fundamental discoveries, regardless of whether they led to new medicines, and she felt isolated from the patients she was driven to help. What she wanted was to work on new medicines, something she couldn’t do within her role.

Reshma Kewalramani
Reshma Kewalramani, CEO and president at Vertex Pharmaceuticals, the first female CEO of a large biotech company.

“I realized if I wanted to do that—drug discovery, clinical trials, make new medicines—that actually happens in industry, whether it’s biotech or pharma,” Kewalramani said, “that’s really the heart of where that action is.”

That left her with a choice. She could remain in Boston, surrounded by friends and family, continuing to practice medicine—the career she had always envisioned—or she could take a risk. And, as Kewalramani knew, risk was often proportional to reward.

So, she and her husband quit their jobs. They packed up their 6-month-old twins, left Kewalramani’s beloved Boston behind, and moved to California, where they remained for the next 13 years. During that time, Kewalramani rose through various roles before becoming Amgen’s vice president and head of the U.S. medical organization in 2014.

Kewalramani returned to Boston in 2017, taking a leadership role at Vertex Pharmaceuticals, before rising to the position of CEO and president in 2020. And, as the first female CEO of a large biotech company, Kewalramani exemplifies the need for entrepreneurial leaders who place their values at the forefront. She has overseen significant advances in treatments for cystic fibrosis, sickle cell disease, beta thalassemia, APOL1-mediated kidney disease, pain, type 1 diabetes, and more.

Work within health care is complex, fraught with risk, and essential for any healthy, thriving community. By comparison, Kewalramani said, leadership and decision making at Vertex is actually quite simple: The “goal is very clear. It is to make medicines that transform, if not cure, diseases. And, so when it comes down to setting priorities, allocating resources, making decisions, that is the north star.”

The Relentless Pursuit of Innovation

With a market cap of roughly $75 billion, Vertex has grown into an undeniable leader within Boston’s thriving biotech industry. Vertex is a “disease-first company,” an organization structured around the drive to treat specific diseases, rather than a given technology, and under Kewalramani’s leadership they are committed to producing innovative scientific discoveries that provide a clear and direct benefit to patients in need.

Resma Kewalramani
Under Kewalramani’s leadership, Vertex Pharmaceuticals has grown into an undeniable leader within Boston’s thriving biotech industry.

“People are surprised because it’s almost as if we’ve come out of the dark and emerged front and center,” Kewalramani said, “but like most things, it wasn’t an overnight success.”

Kewalramani builds upon more than 30 years of prudent decision making, taking Vertex from its origins as a small molecule company, focused on producing medications typically taken by mouth each day, toward regenerative medicines, treatments designed to transform or cure diseases.

But, success is not a linear path, and complacency can damage even the most competitive product. To prove it, Kewalramani points to Vertex’s recent history. In 2011, Vertex launched Incivek, the fastest molecule of its time to rise from zero to $1 billion in revenue. Incivek also became the fastest molecule of its time to fall from $1 billion back down to zero.

“We don’t do incremental improvement, we innovate to transform or cure, and we serially innovate. We simply are relentless in that way, and our own history has taught us to be like that.”

Today, Kewalramani is on the cusp of bringing Vertex’s work with CRISPR/Cas9 to patients. Vertex also is pursuing the benefits of mRNA technology for patients with cystic fibrosis. And, through its work in cell therapy, Kewalramani said, Vertex has treated two patients with type 1 diabetes—one has become insulin free and the other has received tremendous benefit. “It’s quite amazing, because just 30 years ago, we were a small molecule company.”

Opportunities Await

The pandemic years again have proven that health care impacts everyone. “So, whether or not we are interested in health care as careers,” Kewalramani said, “it’s really important to understand the science behind the medicine and work collectively, especially as Babson students, to make sure that health care is front and center, that we continue to innovate to make new medicines, and that these medicines are accessible to patients.”

“We don’t do incremental improvement, we innovate to transform or cure, and we serially innovate. We simply are relentless in that way, and our own history has taught us to be like that.”
Reshma Kewalramani, CEO and president of Vertex Pharmaceuticals

Kewalramani also believes that we are on the brink of a movement from chronic therapies, requiring medicines taken daily by mouth over lifetimes, to curative therapies, one-and-done treatments with the goal to radically transform, if not cure, diseases. With this change comes enormous opportunities for those who are prepared to lead with their values, think entrepreneurially, and take risks.

It’s a path that Kewalramani has carved into an impactful, successful career, and it’s advice she is eager to share with Babson graduates when she addresses them at Commencement. “Do things that make you uncomfortable,” she said. “Know that you’re going to have a team of people around you, and that it’s actually more important to know how to ask all the right questions than it is to have all the right answers.”

Posted in Community

More from Community »

Latest Stories

Farrah Narkiewicz and Rob Major sit and talk at Trim Dining Hall
The Regular Crowd Shuffles In: Lunchtime at Trim  Trim Dining Hall may be a key part of everyday life for many Babson students, but a slew of faculty and staff members also make it part of their daily routine. At lunchtime, they file into the dining hall, seeking food and camaraderie.
By
John Crawford
Senior Journalist
John Crawford
A writer for Babson Thought & Action and the Babson Magazine, John Crawford has been telling the College’s entrepreneurial story for more than 15 years. Assignments for Babson have taken him from Rwanda to El Salvador, from the sweet-smelling factory of a Pennsylvania candy maker, to the stately Atlanta headquarters of an NFL owner, to the bustling office of a New York City fashion designer. Beyond his work for Babson, he has written articles and essays for The Philadelphia Inquirer, Notre Dame Magazine, The Good Men Project, and other publications. He can be found on Twitter, @crawfordwriter, where he tweets about climate change.
September 4, 2025

Posted in Community

Babson Study Reveals the Power of Customer Kindness New Babson-funded research shows that customer kindness can boost employee satisfaction, reduce turnover, and spark a cycle of positivity in service industries.
By
Hillary Chabot
Writer
Hillary Chabot
Hillary Chabot is a writer for Babson Thought & Action and Babson Magazine. An award-winning journalist, she is known for her insightful reporting and dedication to detailed storytelling. With a career spanning over two decades, she has covered a wide range of topics, from presidential campaigns and government policy to neighborhood issues and investigative series. As a reporter for The Boston Herald, Hillary earned a reputation for tenacity and integrity. Her work at Babson College fuels her passions—to learn something new every day and conduct thoughtful, empathic interviews. She’s thrilled to be at Babson College, where students, faculty, staff members and classes provide compelling copy daily.
September 3, 2025

Posted in Community, Insights

Three photos in a side-by-side collage depict Michael Kopelman coaching, Brady Anderson in action, and the doubles team celebrating
Courting Success: How Babson Tennis Teams Transformed into National Powerhouses With championships and top-tier recruiting classes, Babson Director of Tennis Michael Kopelman has overseen the transformation of the men’s and women’s programs into national powerhouses.
By
Scott Dietz
Writer
Scott Dietz
Scott Dietz is Babson College's Associate Athletic Director for Strategic Communications. Dietz is responsible for the department's internal and external communications, including branding, campus engagement, marketing, social media, sponsorships and website management. Additional duties consist of event coverage, facilitation of interview requests, media pitching, video content, writing and editing. Before Babson, Dietz spent 13-plus years at fellow NEWMAC institution Wheaton College, worked for the NFL, New England Patriots, and in the media relations department with the NBA's Cleveland Cavaliers. A native of South Park, PA, Dietz began his sports information career at Westminster College.
September 2, 2025

Posted in Community